PMID- 17019707
OWN - NLM
STAT- MEDLINE
DCOM- 20070208
LR  - 20160303
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 120
IP  - 1
DP  - 2007 Jan 1
TI  - Annexin-I as a potential target for green tea extract induced actin remodeling.
PG  - 111-20
AB  - Using a multistep human urothelial model, we previously showed that green tea 
      extract (GTE) selectively modulates actin remodeling in transformed cells 
      (MC-T11), which resulted in increased cell adhesion and reduced cell motility (Lu 
      et al., Clin Cancer Res 2005;11:1675-83). This study further analyzed which actin 
      binding proteins (ABPs) might be involved in this process. Proteomic profiles of 
      GTE treated and untreated MC-T11 cells using two-dimensional gel electrophoresis 
      coupled with liquid chromatography tandem mass spectrometry (LC/MS/MS) and 
      matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) 
      identified 20 GTE-induced proteins. Among them, 3 were ABPs (tropomodulin, 
      cofilin and annexin-I), and only annexin-I showed a dose- and time-dependent 
      expression. The increased annexin-I correlated with actin remodeling, and was the 
      result of transcription level up-regulation, as determined by RT-PCR, pull-down 
      immunoblot and siRNA analyses. 5-Azacytidine, a DNA methylation inhibitor, 
      exhibited no effect on annexin-I expression when used alone, but had an additive 
      effect for GTE-induced annexin-I expression. Immunohistochemistry of bladder 
      cancer tissue array showed a decrease of annexin-I expression in carcinoma in 
      situ and low grade papillary carcinoma (n = 32, 0% positive) compared to nontumor 
      urothelium (n = 18, 89% positive) (p < 0.001 by Fisher exact test), but increased 
      in some (6 of 15, 40%) high-grade tumors. Together, GTE induced annexin-I 
      expression plays a role in regulating actin remodeling and decreased annexin-I 
      expression is a common event in early stage of bladder cancer development.
FAU - Xiao, Gui-Shan
AU  - Xiao GS
AD  - Department of Clinic Molecular Pharmacology, Comprehensive Cancer Center at City 
      of Hope National Medical Center, Duarte, California, USA.
FAU - Jin, Yu-Sheng
AU  - Jin YS
FAU - Lu, Qing-Yi
AU  - Lu QY
FAU - Zhang, Zuo-Feng
AU  - Zhang ZF
FAU - Belldegrun, Arie
AU  - Belldegrun A
FAU - Figlin, Robert
AU  - Figlin R
FAU - Pantuck, Allan
AU  - Pantuck A
FAU - Yen, Yun
AU  - Yen Y
FAU - Li, Frederick
AU  - Li F
FAU - Rao, Jianyu
AU  - Rao J
LA  - eng
GR  - U01CA96116/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Actins)
RN  - 0 (Annexin A1)
RN  - 0 (Plant Extracts)
RN  - 0 (Proteome)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Tea)
SB  - IM
MH  - Actins/*metabolism
MH  - Annexin A1/antagonists & inhibitors/genetics/*metabolism
MH  - Carcinoma in Situ/metabolism/pathology
MH  - Carcinoma, Papillary/metabolism/pathology
MH  - Case-Control Studies
MH  - Cell Line, Transformed
MH  - Electrophoresis, Gel, Two-Dimensional
MH  - Fluorescent Antibody Technique
MH  - Humans
MH  - Immunoblotting
MH  - Immunoenzyme Techniques
MH  - Immunoprecipitation
MH  - Peptide Mapping
MH  - Plant Extracts/*pharmacology
MH  - Proteome
MH  - RNA, Small Interfering/pharmacology
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
MH  - *Tea
MH  - Tissue Array Analysis
MH  - Urinary Bladder Neoplasms/metabolism/pathology
MH  - Urothelium/metabolism/pathology
EDAT- 2006/10/05 09:00
MHDA- 2007/02/09 09:00
CRDT- 2006/10/05 09:00
PHST- 2006/10/05 09:00 [pubmed]
PHST- 2007/02/09 09:00 [medline]
PHST- 2006/10/05 09:00 [entrez]
AID - 10.1002/ijc.22164 [doi]
PST - ppublish
SO  - Int J Cancer. 2007 Jan 1;120(1):111-20. doi: 10.1002/ijc.22164.